171 related articles for article (PubMed ID: 14965834)
21. Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers.
Sanchez JL; Trofa AF; Taylor DN; Kuschner RA; DeFraites RF; Craig SC; Rao MR; Clemens JD; Svennerholm AM; Sadoff JC
J Infect Dis; 1993 Jun; 167(6):1446-9. PubMed ID: 8501336
[TBL] [Abstract][Full Text] [Related]
22. [A safety assessment on adverse reaction of recombinant B-subunit/inactivated whole cell oral cholera vaccine among non-infected population].
Zhang XP; Chen EF; Lv HK
Zhongguo Yi Miao He Mian Yi; 2009 Jun; 15(3):255-8. PubMed ID: 20084896
[TBL] [Abstract][Full Text] [Related]
23. Analysis of efficacy of CVD 103-HgR live oral cholera vaccine against all-cause travellers' diarrhoea in a randomised, double-blind, placebo-controlled study.
Leyten EM; Soonawala D; Schultsz C; Herzog C; Ligthelm RJ; Wijnands S; Visser LG
Vaccine; 2005 Oct; 23(43):5120-6. PubMed ID: 15982790
[TBL] [Abstract][Full Text] [Related]
24. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
25. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission.
Ali M; Emch M; Yunus M; Sack D; Lopez AL; Holmgren J; Clemens J
Pediatr Infect Dis J; 2008 Jan; 27(1):33-7. PubMed ID: 18162935
[TBL] [Abstract][Full Text] [Related]
26. Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy.
Hashim R; Khatib AM; Enwere G; Park JK; Reyburn R; Ali M; Chang NY; Kim DR; Ley B; Thriemer K; Lopez AL; Clemens JD; Deen JL; Shin S; Schaetti C; Hutubessy R; Aguado MT; Kieny MP; Sack D; Obaro S; Shaame AJ; Ali SM; Saleh AA; von Seidlein L; Jiddawi MS
PLoS Negl Trop Dis; 2012; 6(7):e1743. PubMed ID: 22848772
[TBL] [Abstract][Full Text] [Related]
27. [Controlled results of the oral anticholera vaccine from the Institut Pasteur during the Shaba-Zaire epidemic in 1983].
Dodin A; Masengo B; Loucq C
C R Acad Sci III; 1984; 299(7):205-7. PubMed ID: 6435818
[TBL] [Abstract][Full Text] [Related]
28. Oral vaccination with liposome-encapsulated recombinant fusion peptide of urease B epitope and cholera toxin B subunit affords prophylactic and therapeutic effects against H. pylori infection in BALB/c mice.
Zhao W; Wu W; Xu X
Vaccine; 2007 Nov; 25(44):7664-73. PubMed ID: 17913305
[TBL] [Abstract][Full Text] [Related]
29. Cost-benefit of WC/rBS oral cholera vaccine for vaccination against ETEC-caused travelers' diarrhea.
Lundkvist J; Steffen R; Jönsson B
J Travel Med; 2009; 16(1):28-34. PubMed ID: 19192125
[TBL] [Abstract][Full Text] [Related]
30. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
31. Immune response to influenza vaccination in children and adults with asthma: effect of corticosteroid therapy.
Hanania NA; Sockrider M; Castro M; Holbrook JT; Tonascia J; Wise R; Atmar RL;
J Allergy Clin Immunol; 2004 Apr; 113(4):717-24. PubMed ID: 15100679
[TBL] [Abstract][Full Text] [Related]
32. Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding.
Ahmed T; Svennerholm AM; Al Tarique A; Sultana GN; Qadri F
Vaccine; 2009 Feb; 27(9):1433-9. PubMed ID: 19146904
[TBL] [Abstract][Full Text] [Related]
33. Formulation in tablets of a cholera whole cells inactivated vaccine candidate.
Talavera A; Año G; Pino Y; Castaño J; Uribarri E; Riverón L; Gil S; Fernández S; Cedré B; Valmaseda T; Pérez JL; Infante JF; García L; Sierra G
Vaccine; 2006 Apr; 24(16):3381-7. PubMed ID: 16460846
[TBL] [Abstract][Full Text] [Related]
34. Clinical experience with inactivated, virosomal influenza vaccine.
de Bruijn IA; Nauta J; Cramer WC; Gerez L; Palache AM
Vaccine; 2005 Jul; 23 Suppl 1():S39-49. PubMed ID: 16005120
[TBL] [Abstract][Full Text] [Related]
35. [Comparison of the kinesis of immune responses in mice vaccinated by different kinds of recombinant hepatitis B vaccines].
Hu ZY; He P; Fang X; Qiu SH; Liang ZL; Li HM; Zhuang H
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):810-4. PubMed ID: 19103120
[TBL] [Abstract][Full Text] [Related]
36. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
Hagenaars N; Mastrobattista E; Glansbeek H; Heldens J; van den Bosch H; Schijns V; Betbeder D; Vromans H; Jiskoot W
Vaccine; 2008 Dec; 26(51):6555-63. PubMed ID: 18848856
[TBL] [Abstract][Full Text] [Related]
37. Experimental immunisation and protection of guinea pigs with Vibrio cholerae toxoid and mucinases, neuraminidase and proteinase.
Stewart-Tull DE; Lucas C; Bleakley CR
Vaccine; 2004 Jun; 22(17-18):2137-45. PubMed ID: 15149770
[TBL] [Abstract][Full Text] [Related]
38. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.
Tejedor JC; Omeñaca F; García-Sicilia J; Verdaguer J; Van Esso D; Esporrín C; Molina V; Muro M; Marés J; Enrubia M; Moraga F; García-Corbeira P; Dobbelaere K; Schuerman L;
Pediatr Infect Dis J; 2004 Dec; 23(12):1109-15. PubMed ID: 15626947
[TBL] [Abstract][Full Text] [Related]
40. [Safety and immunogenicity of Bilive combined hepatitis A and B vaccine].
Zhao YL; Chen YG; Li J; Han GX; Tian C; Liang JL; Li G; Wang ZG; Zhu YG; Tian ZN; Zhang HY; Wan ZJ; Liang ZL; Bi SL
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):470-3. PubMed ID: 15231119
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
